Peer-reviewedCC BY-NC-NDJournal of Investigative Dermatology
Real-Life Performance of the Dermatology Long-Term Life Impact Measure (DLLIM) in Atopic Dermatitis: An International Study of 15,450 Patients
Abstract
To the Editor, Existing dermatological quality-of-life instruments primarily assess short-term burden and psychosocial distress, leaving a gap in the evaluation of long-term consequences (Ezzedine et al, 2025). The Dermatology Long-Term Life Impact Measure (DLLIM) (Silverberg et al, 2025c) was recently developed to address this need. It is a valid and reliable instrument designed to quantify the enduring effects of chronic skin conditions on life trajectories and decision-making. We report an evaluation of the DLLIM in real-life conditions — to our knowledge previously unreported — within an international cohort of patients with atopic dermatitis (AD), across four distinct disease-course groups.
Related
- Performance gaps in zoonotic disease surveillance: An evaluation of the contagious pustular dermatitis system in West Mamprusi, Ghana, 2024
- The Safety of Melasma Treatment in Vitiligo Patients: An International E‐Delphi Study
- Clinical Variability and Genotype Driven Outcomes in an International Cohort of 14 Pediatric FIG4 Patients.
- The ethical and regulatory framework of medical artificial intelligence (AI) system’s behavioral performance for image-based diagnostics: An ethical evaluation of the International and European Union Scope
- Outcomes and prognostic factors in patients with systemic mastocytosis and an associated myeloid neoplasm: an international ECNM registry study
BibTeX
@article{aslanian2026reallife,
title = {{Real-Life Performance of the Dermatology Long-Term Life Impact Measure (DLLIM) in Atopic Dermatitis: An International Study of 15,450 Patients}},
author = {Flavia Pretti Aslanian and Bruno Halioua and Jerry Tan and Chaoying Gu and Thomas Luger and Julien Seneschal and Roni Dodiuk-Gad and Roberto Takaoka and Cita Rosita Sigit Prakoeswa and Ann'Laure Demessant-Flavigny and Caroline Le Floc'H and Nabil Kerrouche and Stéphanie Merhand and Wendy Smith Begolka and África Luca de Tena Smith and Shulamit Burstein and Delphine Kerob and Charles Taieb and Charbel Skayem and Abraham Getachew Kelbore and Laurent Misery and Therdpong Tempark and Alexander Stratigos and Martin Steinhoff and Jonathan Silverberg},
journal = {Journal of Investigative Dermatology},
year = {2026},
month = sep,
doi = {10.1016/j.jid.2026.07.036},
url = {https://u-bordeaux.hal.science/hal-05749407v1},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Real-Life Performance of the Dermatology Long-Term Life Impact Measure (DLLIM) in Atopic Dermatitis: An International Study of 15,450 Patients
AU - Flavia Pretti Aslanian
AU - Bruno Halioua
AU - Jerry Tan
AU - Chaoying Gu
AU - Thomas Luger
AU - Julien Seneschal
AU - Roni Dodiuk-Gad
AU - Roberto Takaoka
AU - Cita Rosita Sigit Prakoeswa
AU - Ann'Laure Demessant-Flavigny
AU - Caroline Le Floc'H
AU - Nabil Kerrouche
AU - Stéphanie Merhand
AU - Wendy Smith Begolka
AU - África Luca de Tena Smith
AU - Shulamit Burstein
AU - Delphine Kerob
AU - Charles Taieb
AU - Charbel Skayem
AU - Abraham Getachew Kelbore
AU - Laurent Misery
AU - Therdpong Tempark
AU - Alexander Stratigos
AU - Martin Steinhoff
AU - Jonathan Silverberg
PY - 2026
DA - 2026/09/14
JO - Journal of Investigative Dermatology
DO - 10.1016/j.jid.2026.07.036
UR - https://u-bordeaux.hal.science/hal-05749407v1
AB - To the Editor, Existing dermatological quality-of-life instruments primarily assess short-term burden and psychosocial distress, leaving a gap in the evaluation of long-term consequences (Ezzedine et al, 2025). The Dermatology Long-Term Life Impact Measure (DLLIM) (Silverberg et al, 2025c) was recently developed to address this need. It is a valid and reliable instrument designed to quantify the enduring effects of chronic skin conditions on life trajectories and decision-making. We report an evaluation of the DLLIM in real-life conditions — to our knowledge previously unreported — within an international cohort of patients with atopic dermatitis (AD), across four distinct disease-course groups.
SN - 0022-202X
SN - 1523-1747
ER -